| Pay vs Performance Disclosure - USD ($) | 12 Months Ended |
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
| Pay vs Performance Disclosure [Table] | | | |
| Pay vs Performance [Table Text Block] | Value of Initial Fixed $100 Investment Based on (3) Year Summary Compensation Table Total for CEO ($) (1) Compensation Actually Paid to CEO ($) (1) (2) Average Summary Compensation Table Total for Non-CEO Named Executive Officers ($) (1) Average Compensation Actually Paid to Non-CEO Named Executive Officers ($) (1)(2) Total Shareholder Return Nasdaq Composite (IXIC) Total Shareholder Return Nasdaq Biotechnology (NBI) Total Shareholder Return Net Income (Loss) 2022 3,966,762 2,370,563 1,597,727 1,041,930 16 109 105 (136,639,466) 2021 5,885,495 (1,327,347) 1,836,454 (862,863) 29 163 118 (119,150,679) 2020 2,236,790 19,820,002 3,671,696 5,382,326 115 134 118 (80,523,002) (1) The CEO for 2022, 2021, and 2020 is Dr. Geoff McDonough . The Non-CEO NEOs for whom the average compensation is presented in this table for 2022 and 2021 are Dr. Matthew Norkunas, Dr. Douglas Kerr, Dr. Matthew Stanton and Dr. Tracy Zimmerman, and for 2020 are Dr. Matthew Norkunas and Dr. Tracy Zimmermann. (2) The amounts shown as Compensation Actually Paid have been calculated in accordance with SEC rules and do not reflect compensation actually realized or received by our NEOs. These amounts reflect total compensation as set forth in the Summary Compensation Table for each year, adjusted as described below. (3) The peer group Total Shareholder Return utilizes the Nasdaq Composite Index and the Nasdaq Biotechnology Index. Total Shareholder Return illustrates the value, as of the last day of the indicated fiscal year, of an investment of $100 in the company’s common stock on June 11, 2020 (the effective date of our Registration Statement on Form S-1 filed with the SEC in connection with our initial public offering). | | |
| Named Executive Officers, Footnote [Text Block] | (1) The CEO for 2022, 2021, and 2020 is Dr. Geoff McDonough . The Non-CEO NEOs for whom the average compensation is presented in this table for 2022 and 2021 are Dr. Matthew Norkunas, Dr. Douglas Kerr, Dr. Matthew Stanton and Dr. Tracy Zimmerman, and for 2020 are Dr. Matthew Norkunas and Dr. Tracy Zimmermann. | | |
| Peer Group Issuers, Footnote [Text Block] | (3) The peer group Total Shareholder Return utilizes the Nasdaq Composite Index and the Nasdaq Biotechnology Index. Total Shareholder Return illustrates the value, as of the last day of the indicated fiscal year, of an investment of $100 in the company’s common stock on June 11, 2020 (the effective date of our Registration Statement on Form S-1 filed with the SEC in connection with our initial public offering). | | |
| PEO Total Compensation Amount | $ 3,966,762 | $ 5,885,495 | $ 2,236,790 |
| PEO Actually Paid Compensation Amount | $ 2,370,563 | (1,327,347) | 19,820,002 |
| Adjustment To PEO Compensation, Footnote [Text Block] | 2022 2021 2020 Adjustments CEO ($) Non-CEO NEOs* ($) CEO ($) Non-CEO NEOs* ($) CEO ($) Non-CEO NEOs* ($) Total Compensation from Summary Compensation Table 3,966,762 1,597,727 5,885,495 1,836,454 2,236,790 3,671,696 Adjustments for stock and option awards: (Subtraction): Aggregate value for stock awards and option awards included in Summary Compensation Table for the covered fiscal year (3,027,675) (960,782) (4,950,122) (1,213,010) (1,379,905) (3,238,913) Addition: Fair value at year end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end 1,525,800 484,183 936,844 228,821 4,937,828 4,230,537 Addition (Subtraction): Change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year end (427,413) (192,681) (2,155,228) (1,512,235) 10,123,149 597,037 Addition: Vesting date fair value of awards granted and vested during the covered fiscal year 468,057 148,537 — — — — Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year (134,968) (35,054) (1,044,336) (202,893) 3,902,140 121,969 Compensation Actually Paid (as calculated) 2,370,563 1,041,930 (1,327,347) (862,863) 19,820,002 5,382,326 *Amounts presented are averages for the entire group of Non-CEO NEOs. | | |
| Non-PEO NEO Average Total Compensation Amount | $ 1,597,727 | 1,836,454 | 3,671,696 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 1,041,930 | (862,863) | 5,382,326 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | 2022 2021 2020 Adjustments CEO ($) Non-CEO NEOs* ($) CEO ($) Non-CEO NEOs* ($) CEO ($) Non-CEO NEOs* ($) Total Compensation from Summary Compensation Table 3,966,762 1,597,727 5,885,495 1,836,454 2,236,790 3,671,696 Adjustments for stock and option awards: (Subtraction): Aggregate value for stock awards and option awards included in Summary Compensation Table for the covered fiscal year (3,027,675) (960,782) (4,950,122) (1,213,010) (1,379,905) (3,238,913) Addition: Fair value at year end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end 1,525,800 484,183 936,844 228,821 4,937,828 4,230,537 Addition (Subtraction): Change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year end (427,413) (192,681) (2,155,228) (1,512,235) 10,123,149 597,037 Addition: Vesting date fair value of awards granted and vested during the covered fiscal year 468,057 148,537 — — — — Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year (134,968) (35,054) (1,044,336) (202,893) 3,902,140 121,969 Compensation Actually Paid (as calculated) 2,370,563 1,041,930 (1,327,347) (862,863) 19,820,002 5,382,326 *Amounts presented are averages for the entire group of Non-CEO NEOs. | | |
| Equity Valuation Assumption Difference, Footnote [Text Block] | For the equity values included in the above tables, the valuation assumptions used to calculate fair values of stock options were materially different from those disclosed at the time of the grant of the stock options due to the volatility of our stock prices. The assumptions used in determining fair value of the stock options that vested during 2022, 2021, and 2020, or that were outstanding as of December 31, 2022, 2021, and 2020, as applicable, are as follows: Stock Options Vested During Year or Outstanding on December 31: 2022 2021 2020 Risk-free interest rate 1.35% - 4.26% 0.50% - 1.35% 0.38% - 1.75% Expected volatility 90.2% - 95.2% 74.6% - 91.1% 72.6% - 82.66% Expected dividend yield — — — Expected term (in years) 5 - 6 5 - 6 6 | | |
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Description of Relationship Between NEO Compensation Actually Paid and Company Total Shareholder Return, or TSR The following chart sets forth the relationship between Compensation Actually Paid to our CEO, the average of Compensation Actually Paid to our Non-CEO NEOs, and our TSR over the fiscal three-year period from 2020 through 2022. As set forth and illustrated above, the Compensation Actually Paid for 2021, as calculated in accordance with the SEC Rules, appears negative as a result of significant decreases in fair value of stock options granted to our NEOs at the measurement dates required in the SEC rules as compared to the fair value of such stock options at the grant date. In the fiscal three-year period covered by this disclosure, our stock price has been volatile and valuations have varied greatly throughout each year. As a preclinical, non-revenue-generating company, we do not consider net income (loss) or stockholder return as factors when establishing or benchmarking our executive compensation. For a discussion of our performance metrics and compensation philosophy, see “Compensation Discussion and Analysis” above. | | |
| Total Shareholder Return Amount | $ 16 | 29 | 115 |
| Net Income (Loss) | $ (136,639,466) | $ (119,150,679) | $ (80,523,002) |
| PEO Name | Dr. Geoff McDonough | | |
| Risk-free interest rate Minimum | 1.35% | 0.50% | 0.38% |
| Risk-free interest rate Maximum | 4.26% | 1.35% | 1.75% |
| Expected volatility Minimum | 90.20% | 74.60% | 72.60% |
| Expected volatility Maximum | 95.20% | 91.10% | 82.66% |
| Expected term Minimum (in years) | 5 years | 5 years | |
| Expected term Maximum (in years) | 6 years | 6 years | |
| Nasdaq Composite (IXIC) Total Shareholder Return | $ 109 | $ 163 | $ 134 |
| Nasdaq Biotechnology (NBI) Total Shareholder Return | 105 | 118 | $ 118 |
| Expected term (in years) | | | 6 years |
| PEO [Member] | Aggregate value for stock awards and option awards included in Summary Compensation Table for the covered fiscal year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (3,027,675) | (4,950,122) | $ (1,379,905) |
| PEO [Member] | Fair value at year end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 1,525,800 | 936,844 | 4,937,828 |
| PEO [Member] | Change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year end | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (427,413) | (2,155,228) | 10,123,149 |
| PEO [Member] | Vesting date fair value of awards granted and vested during the covered fiscal year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 468,057 | | |
| PEO [Member] | Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (134,968) | (1,044,336) | 3,902,140 |
| Non-PEO NEO [Member] | Aggregate value for stock awards and option awards included in Summary Compensation Table for the covered fiscal year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (960,782) | (1,213,010) | (3,238,913) |
| Non-PEO NEO [Member] | Fair value at year end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 484,183 | 228,821 | 4,230,537 |
| Non-PEO NEO [Member] | Change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year end | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (192,681) | (1,512,235) | 597,037 |
| Non-PEO NEO [Member] | Vesting date fair value of awards granted and vested during the covered fiscal year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 148,537 | | |
| Non-PEO NEO [Member] | Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | $ (35,054) | $ (202,893) | $ 121,969 |
